• ChemFaces is a professional high-purity natural products manufacturer.
  • Product Intended Use
  • 1. Reference standards
  • 2. Pharmacological research
  • 3. Inhibitors
  • Home
  • Natural Products
  • Bioactive
  • Screening Libraries
  • Hot Products
  • Plant Catalog
  • Customer Support
  • Product Use Citation
  • About Us
  • Contact Us
  • Natural Products
    Chenodeoxycholic acid
    Chenodeoxycholic acid
    Information
    CAS No. 474-25-9 Price $30 / 20mg
    Catalog No.CFN90478Purity>=98%
    Molecular Weight392.57Type of CompoundSteroids
    FormulaC24H40O4Physical DescriptionCryst.
    Download     COA    MSDSSimilar structuralComparison (Web)
    How to Order
    Orders via your E-mail:

    1. Product number / Name / CAS No.
    2. Delivery address
    3. Ordering/billing address
    4. Contact information
    Sent to Email: info@chemfaces.com
    Contact Us
    Order & Inquiry & Tech Support

    Tel: (0086)-27-84237683
    Fax: (0086)-27-84254680
    E-mail: manager@chemfaces.com
    Address: No. 83, CheCheng Rd., WETDZ, Wuhan, Hubei 430056, PRC
    Delivery time
    Delivery & Payment method

    1. Usually delivery time: Next day delivery by 9:00 a.m. Order now

    2. We accept: Wire transfer & Credit card & Paypal & Western Union
    * Packaging according to customer requirements(5mg, 10mg, 20mg and more). We shipped via FedEx, DHL, UPS, EMS and others courier.
    Our products had been exported to the following research institutions and universities, And still growing.
  • Subang Jaya Medical Centre (Malaysia)
  • Griffith University (Australia)
  • Nicolaus Copernicus Uniwersity (Poland)
  • University of Leipzig (Germany)
  • Universitas Airlangga (Indonesia)
  • University of Fribourg (Switzerland)
  • University of Oslo (Norway)
  • University Medical Center Mainz (Germany)
  • University of Indonesia (Indonesia)
  • Mendel University in Brno (Czech Republic)
  • Ain Shams University (Egypt)
  • More...
  • Package
    Featured Products
    Dihydrocucurbitacin B

    Catalog No: CFN92140
    CAS No: 13201-14-4
    Price: $418/5mg
    Isochlorogenic acid B

    Catalog No: CFN99119
    CAS No: 14534-61-3
    Price: $108/20mg
    Ginsenoside Rk2

    Catalog No: CFN92818
    CAS No: 364779-14-6
    Price: $498/10mg
    Przewaquinone A

    Catalog No: CFN92022
    CAS No: 76843-23-7
    Price: $463/5mg
    1,5-Dicaffeoylquinic acid

    Catalog No: CFN99123
    CAS No: 30964-13-7
    Price: $298/20mg
    Biological Activity
    Description: Chenodeoxycholic acid is a hydrophobic primary bile acid that activates nuclear receptors (FXR) involved in cholesterol metabolism. Chenodeoxycholic acid could reverse obesity in cHF-fed mice, mainly in response to the reduction in food intake.
    Targets: IL Receptor | p38MAPK | PKA
    In vitro:
    J Gastroenterol Hepatol. 2013 May;28(5):823-8.
    Acidic deoxycholic acid and chenodeoxycholic acid induce interleukin-8 production through p38 mitogen-activated protein kinase and protein kinase A in a squamous epithelial model.[Pubmed: 23425072]
    Immune-mediated mucosal inflammation characterized by the production of interleukin (IL)-8 is associated with the development of gastroesophageal reflux disease. The effects of bile acids, which are major components of reflux fluid, on the production of IL-8 and related mechanisms remain unclear. This study aimed to address these questions using an esophageal stratified squamous epithelial model.
    METHODS AND RESULTS:
    Normal human esophageal epithelial cells were seeded on the Transwell inserts and cultured with the air-liquid interface system to establish the model. Bile acids under different pH conditions were added to the apical compartment to examine their effects on IL-8 production and the underlying cellular signaling. Conjugated bile acids under a neutral or acidic condition did not induce IL-8 production, and unconjugated bile acids, deoxycholic acid (DCA), and Chenodeoxycholic acid (CDCA) all significantly induced IL-8 production, dose- and time-dependently, only under weakly acid conditions. Inhibition of p38 mitogen-activated protein kinase (p38 MAPK) and protein kinase A (PKA) attenuated the production of IL-8 induced by acidic DCA and CDCA. Inhibition of PKA did not block the bile acid-induced p38 MAPK activation.
    CONCLUSIONS:
    Compared with conjugated bile acids, the unconjugated bile acids DCA and CDCA are more likely to induce IL-8 production in vivo, especially under weakly acid conditions. This process involves two independent signaling pathways, p38 MAPK and PKA.
    In vivo:
    J Inherit Metab Dis. 2014 Sep;37(5):851-61.
    Liver disease in infancy caused by oxysterol 7 α-hydroxylase deficiency: successful treatment with chenodeoxycholic acid.[Pubmed: 24658845]
    A child of consanguineous parents of Pakistani origin developed jaundice at 5 weeks and then, at 3 months, irritability, a prolonged prothrombin time, a low albumin, and episodes of hypoglycaemia. Investigation showed an elevated alanine aminotransferase with a normal γ-glutamyl-transpeptidase.
    METHODS AND RESULTS:
    Analysis of urine by electrospray ionisation tandem mass spectrometry (ESI-MS/MS) showed that the major peaks were m/z 480 (taurine-conjugated 3β-hydroxy-5-cholenoic acid) and m/z 453 (sulphated 3β-hydroxy-5-cholenoic acid). Analysis of plasma by gas chromatography-mass spectrometry (GC-MS) showed increased concentrations of 3β-hydroxy-5-cholenoic acid, 3β-hydroxy-5-cholestenoic acid and 27-hydroxycholesterol, indicating oxysterol 7 α-hydroxylase deficiency. The patient was homozygous for a mutation (c.1249C>T) in CYP7B1 that alters a highly conserved residue in oxysterol 7 α-hydroxylase (p.R417C) - previously reported in a family with hereditary spastic paraplegia type 5. On treatment with ursodeoxycholic acid (UDCA), his condition was worsening, but on Chenodeoxycholic acid (CDCA), 15 mg/kg/d, he improved rapidly. A biopsy (after 2 weeks on CDCA), showed a giant cell hepatitis, an evolving micronodular cirrhosis, and steatosis. The improvement in liver function on CDCA was associated with a drop in the plasma concentrations and urinary excretions of the 3β-hydroxy-Δ5 bile acids which are considered hepatotoxic. At age 5 years (on CDCA, 6 mg/kg/d), he was thriving with normal liver function. Neurological development was normal apart from a tendency to trip. Examination revealed pes cavus but no upper motor neuron signs.
    CONCLUSIONS:
    The findings in this case suggest that CDCA can reduce the activity of cholesterol 27-hydroxylase - the first step in the acidic pathway for bile acid synthesis.
    J Clin Endocrinol Metab. 2013 Aug;98(8):3351-8.
    Effects of chenodeoxycholic acid on the secretion of gut peptides and fibroblast growth factors in healthy humans.[Pubmed: 23783097]
    We hypothesized that intraduodenal infusions of Chenodeoxycholic acid (CDCA) would stimulate FGF and gut peptide secretion, thereby positively influencing glucose homeostasis.
    METHODS AND RESULTS:
    This randomized, double-blind, placebo-controlled, crossover trial included 12 healthy volunteers who received intraduodenal infusions (2.0 mL/min for 180 minutes) of saline, Chenodeoxycholic acid (5 or 15 mmol/L), and a fatty acid (sodium oleate), either alone or with 5 mmol/L Chenodeoxycholic acid. After 60 minutes, an oral glucose tolerance test (oGTT) was performed. Within the first 60 minutes, high-concentration Chenodeoxycholic acid induced a small but significant increase in GLP-1 and CCK secretion (P = .016 and P =.011), whereas plasma C-peptide, insulin, and glucose were not affected. Attenuated C-peptide and insulin release was observed after the oGTT with 15 mmol/L CDCA (P = .013 and P =.011). Plasma BA and FGF19 levels significantly increased after Chenodeoxycholic acid administration (P = .001 and P < .001).
    CONCLUSIONS:
    Chenodeoxycholic acid modulates GLP-1 and CCK secretion; the effect is small and does not influence glucose levels. The marked increase in plasma BAs and the attenuated insulin release after the oGTT indicate the role of BAs in glycemic control, independent of the incretin axis, and suggest involvement of farnesoid X receptor activation pathways.
    Chenodeoxycholic acid Description
    Source: From the bile.
    Solvent: Chloroform, Dichloromethane, Ethyl Acetate, DMSO, Acetone, etc.
    Storage: Providing storage is as stated on the product vial and the vial is kept tightly sealed, the product can be stored for up to 24 months(2-8C).

    Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20C. Generally, these will be useable for up to two weeks. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.

    Need more advice on solubility, usage and handling? Please email to: service@chemfaces.com

    After receiving: The packaging of the product may have turned upside down during transportation, resulting in the natural compounds adhering to the neck or cap of the vial. take the vial out of its packaging and gently shake to let the compounds fall to the bottom of the vial. for liquid products, centrifuge at 200-500 RPM to gather the liquid at the bottom of the vial. try to avoid loss or contamination during handling.
    Recent ChemFaces New Products and Compounds
    Methylnissolin-3-O-glucoside

    Catalog No: CFN93199
    CAS No: 94367-42-7
    Price: $218/20mg
    Arjunglucoside I

    Catalog No: CFN95049
    CAS No: 62319-70-4
    Price: $268/10mg
    Lappaol F

    Catalog No: CFN95069
    CAS No: 69394-17-8
    Price: $368/10mg
    Miltirone

    Catalog No: CFN98531
    CAS No: 27210-57-7
    Price: $288/5mg
    Pachymic acid

    Catalog No: CFN99590
    CAS No: 29070-92-6
    Price: $268/20mg
    3''-O-Galloylmyricitrin

    Catalog No: CFN95057
    CAS No: 143202-36-2
    Price: $333/5mg
    3-O-Acetyl-16 alpha-hydroxytramete...

    Catalog No: CFN90804
    CAS No: 168293-13-8
    Price: $538/10mg
    Naringin 4'-glucoside

    Catalog No: CFN95014
    CAS No: 17257-21-5
    Price: $338/5mg
    Recently, ChemFaces products have been cited in many studies from excellent and top scientific journals

    Cell. 2018 Jan 11;172(1-2):249-261.e12.
    doi: 10.1016/j.cell.2017.12.019.

    PMID: 29328914

    Mol Cell. 2017 Nov 16;68(4):673-685.e6.
    doi: 10.1016/j.molcel.2017.10.022.

    PMID: 29149595

    Scientific Reports 2017 Dec 11;7(1):17332.
    doi: 10.1038/s41598-017-17427-6.

    PMID: 29230013

    Molecules. 2017 Oct 27;22(11). pii: E1829.
    doi: 10.3390/molecules22111829.

    PMID: 29077044

    J Cell Biochem. 2018 Feb;119(2):2231-2239.
    doi: 10.1002/jcb.26385.

    PMID: 28857247

    Phytomedicine. 2018 Feb 1;40:37-47.
    doi:10.1016/j.phymed.2017.12.030

    PMID: 29496173
    Calculate Dilution Ratios(Only for Reference)
    1 mg 5 mg 10 mg 20 mg 25 mg
    1 mM 2.5473 mL 12.7366 mL 25.4732 mL 50.9463 mL 63.6829 mL
    5 mM 0.5095 mL 2.5473 mL 5.0946 mL 10.1893 mL 12.7366 mL
    10 mM 0.2547 mL 1.2737 mL 2.5473 mL 5.0946 mL 6.3683 mL
    50 mM 0.0509 mL 0.2547 mL 0.5095 mL 1.0189 mL 1.2737 mL
    100 mM 0.0255 mL 0.1274 mL 0.2547 mL 0.5095 mL 0.6368 mL
    * Note: If you are in the process of experiment, it's need to make the dilution ratios of the samples. The dilution data of the sheet for your reference. Normally, it's can get a better solubility within lower of Concentrations.
    Protocol
    Animal Research:
    Int J Obes (Lond). 2014 Aug;38(8):1027-34.
    Enhancement of brown fat thermogenesis using chenodeoxycholic acid in mice.[Pubmed: 24310401 ]
    In this study, the effects of another natural BA, Chenodeoxycholic acid (CDCA), on dietary obesity, UCP1 in both interscapular BAT and in white adipose tissue (brite cells in WAT), were characterized in dietary-obese mice.
    METHODS AND RESULTS:
    Mice were then fed either (i) for 8 weeks with cHF or with cHF with two different doses (0.5%, 1%; wt wt(-1)) of Chenodeoxycholic acid (8-week reversion). In the 8-week reversion, the Chenodeoxycholic acid intervention resulted in a dose-dependent reduction of obesity, dyslipidaemia and glucose intolerance, which could be largely explained by a transient decrease in food intake. The 3-week reversion revealed mild Chenodeoxycholic acid-dependent and food intake-independent induction of UCP1-mediated thermogenesis in interscapular BAT, negligible increase of UCP1 in subcutaneous WAT and a shift from carbohydrate to lipid oxidation.
    CONCLUSIONS:
    Chenodeoxycholic acid could reverse obesity in cHF-fed mice, mainly in response to the reduction in food intake, an effect probably occuring but neglected in previous studies using cholic acid. Nevertheless, Chenodeoxycholic acid-dependent and food intake-independent induction of UCP1 in BAT (but not in WAT) could contribute to the reduction in adiposity and to the stabilization of the lean phenotype.